| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 67 | 2024 | 4251 | 6.160 |
Why?
|
| Cryosurgery | 32 | 2023 | 474 | 5.740 |
Why?
|
| Tomography, X-Ray Computed | 158 | 2024 | 20571 | 5.450 |
Why?
|
| Radiography, Interventional | 33 | 2021 | 1121 | 4.650 |
Why?
|
| Urography | 19 | 2018 | 316 | 4.180 |
Why?
|
| Carcinoma, Renal Cell | 31 | 2023 | 3165 | 3.330 |
Why?
|
| Liver Neoplasms | 40 | 2021 | 4319 | 3.310 |
Why?
|
| Kidney Diseases, Cystic | 14 | 2023 | 183 | 3.130 |
Why?
|
| Catheter Ablation | 39 | 2023 | 2751 | 2.900 |
Why?
|
| Biopsy, Needle | 37 | 2013 | 1626 | 2.750 |
Why?
|
| Radiography, Abdominal | 15 | 2023 | 534 | 2.260 |
Why?
|
| Radiology, Interventional | 21 | 2024 | 476 | 2.120 |
Why?
|
| Ablation Techniques | 7 | 2021 | 248 | 2.110 |
Why?
|
| Magnetic Resonance Imaging | 94 | 2024 | 36429 | 2.070 |
Why?
|
| Contrast Media | 40 | 2024 | 5311 | 1.610 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2024 | 148 | 1.570 |
Why?
|
| Angiomyolipoma | 7 | 2019 | 187 | 1.440 |
Why?
|
| Surgery, Computer-Assisted | 12 | 2020 | 1007 | 1.390 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2021 | 2010 | 1.360 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2017 | 187 | 1.320 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2024 | 2223 | 1.310 |
Why?
|
| Hematuria | 7 | 2018 | 233 | 1.300 |
Why?
|
| Microwaves | 9 | 2023 | 185 | 1.280 |
Why?
|
| Diagnostic Imaging | 16 | 2021 | 3530 | 1.230 |
Why?
|
| Radiology | 9 | 2023 | 2113 | 1.170 |
Why?
|
| Abdominal Neoplasms | 8 | 2013 | 287 | 1.150 |
Why?
|
| Positron-Emission Tomography | 11 | 2021 | 6485 | 1.150 |
Why?
|
| Urologic Diseases | 5 | 2017 | 247 | 1.140 |
Why?
|
| Aged, 80 and over | 100 | 2024 | 58986 | 1.090 |
Why?
|
| Drainage | 18 | 2017 | 1157 | 1.050 |
Why?
|
| Biopsy | 21 | 2023 | 6766 | 1.030 |
Why?
|
| Aged | 173 | 2024 | 169310 | 1.000 |
Why?
|
| Kidney Diseases | 11 | 2017 | 2091 | 0.990 |
Why?
|
| Cryotherapy | 8 | 2007 | 159 | 0.990 |
Why?
|
| Incidental Findings | 10 | 2020 | 697 | 0.990 |
Why?
|
| Adrenal Gland Neoplasms | 8 | 2024 | 732 | 0.960 |
Why?
|
| Pelvic Neoplasms | 4 | 2016 | 247 | 0.960 |
Why?
|
| Pancreatitis, Acute Necrotizing | 3 | 2014 | 173 | 0.950 |
Why?
|
| Middle Aged | 189 | 2024 | 220920 | 0.930 |
Why?
|
| Surgical Instruments | 2 | 2017 | 383 | 0.920 |
Why?
|
| Retrospective Studies | 96 | 2024 | 80646 | 0.880 |
Why?
|
| Urologic Neoplasms | 4 | 2019 | 314 | 0.870 |
Why?
|
| Mouth Neoplasms | 19 | 2007 | 596 | 0.860 |
Why?
|
| Sensitivity and Specificity | 42 | 2024 | 14666 | 0.830 |
Why?
|
| Humans | 337 | 2024 | 761572 | 0.810 |
Why?
|
| Iohexol | 10 | 2016 | 204 | 0.810 |
Why?
|
| Male | 199 | 2024 | 360842 | 0.790 |
Why?
|
| Kidney | 23 | 2023 | 7047 | 0.790 |
Why?
|
| Urothelium | 3 | 2019 | 269 | 0.780 |
Why?
|
| Adult | 159 | 2024 | 221203 | 0.770 |
Why?
|
| Gallbladder | 3 | 2014 | 308 | 0.770 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2016 | 2297 | 0.760 |
Why?
|
| Female | 204 | 2024 | 392686 | 0.750 |
Why?
|
| Neoplasm Seeding | 3 | 2013 | 85 | 0.740 |
Why?
|
| Digestive System Neoplasms | 2 | 2011 | 82 | 0.710 |
Why?
|
| Carcinoma, Papillary | 3 | 2016 | 785 | 0.630 |
Why?
|
| Organizational Objectives | 2 | 2018 | 426 | 0.630 |
Why?
|
| Needles | 8 | 2017 | 451 | 0.630 |
Why?
|
| Catheterization | 6 | 2017 | 1428 | 0.630 |
Why?
|
| Cystectomy | 4 | 2024 | 634 | 0.630 |
Why?
|
| Radiation Dosage | 10 | 2017 | 1958 | 0.620 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2018 | 41 | 0.620 |
Why?
|
| Female Urogenital Diseases | 2 | 2017 | 57 | 0.600 |
Why?
|
| Societies, Medical | 8 | 2023 | 3905 | 0.600 |
Why?
|
| Radiopharmaceuticals | 6 | 2018 | 2651 | 0.590 |
Why?
|
| Neoplasm Invasiveness | 5 | 2024 | 3597 | 0.580 |
Why?
|
| Statistics, Nonparametric | 11 | 2015 | 2850 | 0.580 |
Why?
|
| Watchful Waiting | 1 | 2021 | 491 | 0.580 |
Why?
|
| Male Urogenital Diseases | 1 | 2017 | 48 | 0.570 |
Why?
|
| Image Processing, Computer-Assisted | 23 | 2021 | 9002 | 0.570 |
Why?
|
| Digestive System Diseases | 2 | 2017 | 151 | 0.560 |
Why?
|
| Ureteral Calculi | 3 | 2012 | 114 | 0.540 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 1157 | 0.540 |
Why?
|
| Ultrasonography | 21 | 2019 | 5972 | 0.530 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2012 | 517 | 0.530 |
Why?
|
| Diagnosis, Differential | 25 | 2024 | 12975 | 0.530 |
Why?
|
| Paracentesis | 1 | 2016 | 98 | 0.520 |
Why?
|
| Predictive Value of Tests | 23 | 2024 | 15266 | 0.510 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2016 | 333 | 0.500 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2015 | 30 | 0.500 |
Why?
|
| Adrenal Glands | 2 | 2015 | 552 | 0.490 |
Why?
|
| Adipose Tissue | 5 | 2019 | 3312 | 0.480 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2008 | 1159 | 0.480 |
Why?
|
| Neoplasm Staging | 17 | 2021 | 11121 | 0.470 |
Why?
|
| Ascites | 1 | 2016 | 338 | 0.470 |
Why?
|
| Myoglobinuria | 1 | 2014 | 22 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2021 | 9280 | 0.460 |
Why?
|
| Kidney Tubules, Collecting | 2 | 2006 | 162 | 0.460 |
Why?
|
| Ultrasonography, Interventional | 7 | 2012 | 1496 | 0.460 |
Why?
|
| Gastrointestinal Diseases | 3 | 2017 | 1200 | 0.450 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 6 | 2019 | 1222 | 0.440 |
Why?
|
| Radiometry | 3 | 2011 | 813 | 0.430 |
Why?
|
| Lichen Planus, Oral | 2 | 2012 | 57 | 0.430 |
Why?
|
| Liver | 14 | 2019 | 7529 | 0.420 |
Why?
|
| Treatment Outcome | 41 | 2023 | 64684 | 0.420 |
Why?
|
| Subtraction Technique | 3 | 2012 | 512 | 0.420 |
Why?
|
| Ethanol | 4 | 2008 | 1324 | 0.410 |
Why?
|
| Lung Neoplasms | 12 | 2023 | 13382 | 0.410 |
Why?
|
| Pancreatic Diseases | 3 | 2004 | 343 | 0.410 |
Why?
|
| Certification | 1 | 2016 | 418 | 0.410 |
Why?
|
| Pneumothorax | 3 | 2014 | 386 | 0.400 |
Why?
|
| Flank Pain | 1 | 2012 | 43 | 0.400 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 491 | 0.390 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2012 | 75 | 0.390 |
Why?
|
| Pancreatic Neoplasms | 8 | 2018 | 5369 | 0.380 |
Why?
|
| Head and Neck Neoplasms | 6 | 2023 | 2895 | 0.380 |
Why?
|
| Reproducibility of Results | 19 | 2023 | 20099 | 0.380 |
Why?
|
| Fluoroscopy | 7 | 2017 | 947 | 0.380 |
Why?
|
| Curcumin | 1 | 2012 | 98 | 0.370 |
Why?
|
| Body Burden | 1 | 2011 | 158 | 0.370 |
Why?
|
| Testicular Neoplasms | 2 | 2016 | 799 | 0.360 |
Why?
|
| Portal Vein | 4 | 2020 | 431 | 0.360 |
Why?
|
| Phantoms, Imaging | 8 | 2019 | 2526 | 0.360 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2012 | 954 | 0.350 |
Why?
|
| Nephritis | 2 | 2007 | 145 | 0.350 |
Why?
|
| Postoperative Complications | 7 | 2019 | 15633 | 0.350 |
Why?
|
| Pancreatitis | 6 | 2004 | 1096 | 0.350 |
Why?
|
| Carcinoma | 2 | 2012 | 2330 | 0.340 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 293 | 0.340 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 2827 | 0.340 |
Why?
|
| Tomography, Emission-Computed | 2 | 2010 | 1122 | 0.340 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2012 | 200 | 0.330 |
Why?
|
| Leukoplakia, Oral | 6 | 1999 | 77 | 0.330 |
Why?
|
| Urolithiasis | 1 | 2011 | 125 | 0.330 |
Why?
|
| Crohn Disease | 3 | 2017 | 2279 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 1052 | 0.330 |
Why?
|
| Respiration | 2 | 2017 | 1657 | 0.330 |
Why?
|
| Vena Cava, Inferior | 2 | 2007 | 458 | 0.330 |
Why?
|
| Bone Neoplasms | 3 | 2012 | 2529 | 0.320 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2012 | 617 | 0.320 |
Why?
|
| Terminology as Topic | 6 | 2019 | 1530 | 0.320 |
Why?
|
| Informed Consent | 1 | 2015 | 1008 | 0.310 |
Why?
|
| Feasibility Studies | 15 | 2023 | 5247 | 0.310 |
Why?
|
| Hemangioma | 2 | 2016 | 727 | 0.310 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2012 | 304 | 0.310 |
Why?
|
| Abdomen | 10 | 2017 | 1128 | 0.310 |
Why?
|
| Checklist | 1 | 2015 | 827 | 0.300 |
Why?
|
| Splenic Neoplasms | 1 | 2008 | 94 | 0.300 |
Why?
|
| Radiography | 11 | 2023 | 6965 | 0.300 |
Why?
|
| Omentum | 1 | 2009 | 168 | 0.300 |
Why?
|
| Nephrectomy | 4 | 2011 | 937 | 0.300 |
Why?
|
| Liver Diseases | 3 | 2006 | 1298 | 0.290 |
Why?
|
| Laser Therapy | 8 | 2003 | 1092 | 0.290 |
Why?
|
| Myoglobin | 2 | 2011 | 159 | 0.290 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2016 | 4063 | 0.280 |
Why?
|
| Genome | 1 | 2015 | 1740 | 0.280 |
Why?
|
| Lung Diseases | 1 | 2017 | 1909 | 0.280 |
Why?
|
| Renal Veins | 1 | 2007 | 102 | 0.280 |
Why?
|
| Pharyngeal Neoplasms | 4 | 2001 | 113 | 0.280 |
Why?
|
| Preoperative Care | 5 | 2010 | 2242 | 0.280 |
Why?
|
| Decompression, Surgical | 1 | 2012 | 607 | 0.270 |
Why?
|
| Pelvis | 4 | 2016 | 733 | 0.270 |
Why?
|
| Fibrosis | 1 | 2014 | 2049 | 0.270 |
Why?
|
| Mouth Diseases | 3 | 1998 | 241 | 0.270 |
Why?
|
| Image Enhancement | 6 | 2011 | 2885 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 2169 | 0.260 |
Why?
|
| Furosemide | 1 | 2006 | 170 | 0.260 |
Why?
|
| Ureter | 2 | 2012 | 368 | 0.250 |
Why?
|
| False Negative Reactions | 4 | 2018 | 573 | 0.250 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 487 | 0.250 |
Why?
|
| Iothalamic Acid | 1 | 2004 | 17 | 0.250 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2007 | 266 | 0.250 |
Why?
|
| Tumor Burden | 4 | 2016 | 1893 | 0.250 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 1421 | 0.240 |
Why?
|
| Graft vs Host Disease | 4 | 2006 | 3029 | 0.240 |
Why?
|
| Urinary Bladder | 1 | 2011 | 1152 | 0.240 |
Why?
|
| Gases | 1 | 2005 | 204 | 0.240 |
Why?
|
| Medical Oncology | 3 | 2015 | 2321 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 2 | 2009 | 711 | 0.240 |
Why?
|
| Sodium Chloride | 2 | 2006 | 587 | 0.240 |
Why?
|
| Observer Variation | 8 | 2018 | 2606 | 0.240 |
Why?
|
| False Positive Reactions | 4 | 2018 | 957 | 0.240 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2005 | 62 | 0.240 |
Why?
|
| Preoperative Period | 2 | 2019 | 551 | 0.240 |
Why?
|
| Monitoring, Intraoperative | 3 | 2010 | 942 | 0.240 |
Why?
|
| Neoplasms | 10 | 2012 | 22173 | 0.230 |
Why?
|
| Hyperamylasemia | 1 | 2004 | 6 | 0.230 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2006 | 220 | 0.230 |
Why?
|
| Lymphocele | 1 | 2003 | 18 | 0.230 |
Why?
|
| Prospective Studies | 24 | 2020 | 54426 | 0.220 |
Why?
|
| ROC Curve | 7 | 2019 | 3579 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 2273 | 0.220 |
Why?
|
| Boston | 8 | 2014 | 9326 | 0.210 |
Why?
|
| Faculty | 2 | 2023 | 384 | 0.210 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2018 | 1728 | 0.210 |
Why?
|
| Intestinal Diseases | 1 | 2007 | 504 | 0.210 |
Why?
|
| Choristoma | 1 | 2004 | 206 | 0.210 |
Why?
|
| Documentation | 3 | 2019 | 897 | 0.210 |
Why?
|
| Radiology Department, Hospital | 4 | 2005 | 406 | 0.210 |
Why?
|
| Vaginal Neoplasms | 1 | 2003 | 104 | 0.210 |
Why?
|
| User-Computer Interface | 3 | 2015 | 1400 | 0.210 |
Why?
|
| Cystoscopy | 3 | 2019 | 131 | 0.210 |
Why?
|
| Tomography, Spiral Computed | 2 | 2003 | 273 | 0.210 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 21017 | 0.200 |
Why?
|
| Gadolinium DTPA | 3 | 2017 | 823 | 0.200 |
Why?
|
| Pilot Projects | 7 | 2019 | 8633 | 0.200 |
Why?
|
| Consensus | 4 | 2020 | 3123 | 0.200 |
Why?
|
| Bacterial Infections | 2 | 2009 | 1391 | 0.200 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2002 | 173 | 0.190 |
Why?
|
| Lipase | 1 | 2004 | 325 | 0.190 |
Why?
|
| Lipoma | 1 | 2003 | 293 | 0.190 |
Why?
|
| Thoracic Wall | 1 | 2003 | 202 | 0.190 |
Why?
|
| Intestines | 2 | 2010 | 1909 | 0.190 |
Why?
|
| Opportunistic Infections | 1 | 2004 | 376 | 0.180 |
Why?
|
| Thoracic Neoplasms | 1 | 2003 | 267 | 0.180 |
Why?
|
| Mouth Mucosa | 4 | 2007 | 432 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2003 | 215 | 0.180 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2011 | 1118 | 0.180 |
Why?
|
| Mycoses | 1 | 2004 | 386 | 0.180 |
Why?
|
| Spleen | 3 | 2004 | 2295 | 0.180 |
Why?
|
| Forecasting | 4 | 2023 | 2928 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 1 | 2003 | 999 | 0.180 |
Why?
|
| Simplexvirus | 4 | 1986 | 803 | 0.180 |
Why?
|
| Pancreas | 9 | 2004 | 1691 | 0.180 |
Why?
|
| Linear Models | 2 | 2016 | 5872 | 0.170 |
Why?
|
| Thrombosis | 3 | 2007 | 2942 | 0.170 |
Why?
|
| Telomerase | 1 | 2005 | 745 | 0.170 |
Why?
|
| Algorithms | 11 | 2023 | 14032 | 0.170 |
Why?
|
| Follow-Up Studies | 22 | 2021 | 39107 | 0.170 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2020 | 101 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 2244 | 0.170 |
Why?
|
| Pleural Neoplasms | 2 | 2003 | 609 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2006 | 790 | 0.170 |
Why?
|
| Leiomyosarcoma | 1 | 2003 | 422 | 0.170 |
Why?
|
| Microtechnology | 1 | 2019 | 70 | 0.160 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 422 | 0.160 |
Why?
|
| Ureterocele | 1 | 1998 | 28 | 0.160 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 8528 | 0.160 |
Why?
|
| Hepatectomy | 2 | 2014 | 557 | 0.160 |
Why?
|
| Living Donors | 1 | 2003 | 641 | 0.160 |
Why?
|
| Artifacts | 4 | 2019 | 1911 | 0.160 |
Why?
|
| Adenocarcinoma | 5 | 2006 | 6346 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2016 | 3359 | 0.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 262 | 0.150 |
Why?
|
| Lichen Planus | 2 | 1991 | 70 | 0.150 |
Why?
|
| Risk Assessment | 7 | 2015 | 23996 | 0.150 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 1998 | 76 | 0.150 |
Why?
|
| Radiology Information Systems | 3 | 2024 | 529 | 0.150 |
Why?
|
| Research | 2 | 2013 | 1982 | 0.150 |
Why?
|
| Delphi Technique | 2 | 2019 | 846 | 0.150 |
Why?
|
| Vagina | 1 | 2003 | 838 | 0.150 |
Why?
|
| Xerostomia | 2 | 1997 | 94 | 0.150 |
Why?
|
| Motion | 2 | 2021 | 779 | 0.150 |
Why?
|
| Time Factors | 12 | 2014 | 39970 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2022 | 372 | 0.150 |
Why?
|
| Suction | 2 | 2016 | 266 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 3 | 2003 | 2693 | 0.140 |
Why?
|
| Hospital Design and Construction | 1 | 1997 | 33 | 0.140 |
Why?
|
| Bile | 2 | 2012 | 298 | 0.140 |
Why?
|
| Histone Demethylases | 1 | 2020 | 323 | 0.140 |
Why?
|
| Adrenal Gland Diseases | 2 | 1995 | 141 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2003 | 4026 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2003 | 807 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2012 | 1574 | 0.140 |
Why?
|
| Quality Improvement | 6 | 2019 | 3801 | 0.140 |
Why?
|
| Oral Surgical Procedures | 1 | 1998 | 166 | 0.140 |
Why?
|
| Breast | 3 | 2022 | 1967 | 0.140 |
Why?
|
| Hepatic Veins | 2 | 2016 | 112 | 0.140 |
Why?
|
| Internship and Residency | 2 | 2016 | 5882 | 0.130 |
Why?
|
| Neoplasm Metastasis | 6 | 2015 | 4915 | 0.130 |
Why?
|
| Education, Distance | 1 | 2020 | 261 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1998 | 395 | 0.130 |
Why?
|
| Pain | 4 | 2008 | 5073 | 0.130 |
Why?
|
| Perfusion | 1 | 2021 | 1373 | 0.130 |
Why?
|
| Attitude | 1 | 2020 | 775 | 0.130 |
Why?
|
| Guideline Adherence | 3 | 2014 | 2220 | 0.130 |
Why?
|
| Cranial Irradiation | 2 | 1997 | 390 | 0.130 |
Why?
|
| Liver Function Tests | 2 | 2011 | 523 | 0.120 |
Why?
|
| Carbon | 1 | 2019 | 666 | 0.120 |
Why?
|
| Ultrasonic Therapy | 3 | 2007 | 215 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 2759 | 0.120 |
Why?
|
| Bile Ducts | 3 | 2014 | 282 | 0.120 |
Why?
|
| Bethanechol Compounds | 1 | 1994 | 10 | 0.120 |
Why?
|
| Catecholamines | 1 | 2015 | 386 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 1551 | 0.120 |
Why?
|
| Incidence | 6 | 2016 | 21355 | 0.120 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 2915 | 0.120 |
Why?
|
| Disease Progression | 6 | 2019 | 13510 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 1420 | 0.120 |
Why?
|
| Cost Savings | 2 | 2016 | 913 | 0.120 |
Why?
|
| Barium Sulfate | 2 | 2012 | 180 | 0.120 |
Why?
|
| Kidney Calculi | 1 | 1998 | 463 | 0.120 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 1271 | 0.110 |
Why?
|
| Palliative Care | 3 | 2008 | 3598 | 0.110 |
Why?
|
| Sarcoma | 2 | 2021 | 1801 | 0.110 |
Why?
|
| Data Collection | 5 | 2013 | 3322 | 0.110 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 833 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2015 | 2598 | 0.110 |
Why?
|
| Patient Selection | 3 | 2016 | 4244 | 0.110 |
Why?
|
| Adrenalectomy | 1 | 2015 | 346 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 320 | 0.110 |
Why?
|
| Candidiasis, Oral | 3 | 1997 | 57 | 0.110 |
Why?
|
| Medical Audit | 1 | 2015 | 453 | 0.110 |
Why?
|
| Inhalation | 1 | 2014 | 143 | 0.110 |
Why?
|
| Blood Coagulation Tests | 2 | 1991 | 271 | 0.110 |
Why?
|
| Remission, Spontaneous | 2 | 2012 | 384 | 0.110 |
Why?
|
| Proctitis | 2 | 2003 | 41 | 0.110 |
Why?
|
| Respiratory Mechanics | 1 | 2017 | 699 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2020 | 783 | 0.110 |
Why?
|
| Cohort Studies | 10 | 2021 | 41493 | 0.110 |
Why?
|
| Pleural Diseases | 2 | 1995 | 137 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2019 | 1139 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2009 | 710 | 0.100 |
Why?
|
| Prostatic Neoplasms | 5 | 2015 | 11122 | 0.100 |
Why?
|
| Prognosis | 9 | 2019 | 29629 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 1166 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 5 | 2005 | 1624 | 0.100 |
Why?
|
| Risk Factors | 13 | 2016 | 74213 | 0.100 |
Why?
|
| Analysis of Variance | 5 | 2020 | 6228 | 0.100 |
Why?
|
| Adipocytes | 1 | 2019 | 1194 | 0.100 |
Why?
|
| United States | 15 | 2020 | 72335 | 0.100 |
Why?
|
| Hyperplasia | 1 | 2015 | 1152 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2003 | 2330 | 0.100 |
Why?
|
| Wisconsin | 1 | 2011 | 122 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2023 | 3424 | 0.100 |
Why?
|
| Acute Disease | 6 | 2004 | 7237 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2020 | 2332 | 0.090 |
Why?
|
| Attitude of Health Personnel | 3 | 2015 | 3889 | 0.090 |
Why?
|
| Diatrizoate Meglumine | 2 | 2004 | 79 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 588 | 0.090 |
Why?
|
| Patient Positioning | 1 | 2013 | 326 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2021 | 10090 | 0.090 |
Why?
|
| Calcium Oxalate | 1 | 2011 | 75 | 0.090 |
Why?
|
| Adolescent | 15 | 2018 | 88324 | 0.090 |
Why?
|
| Equipment Design | 4 | 2013 | 3511 | 0.090 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2014 | 396 | 0.090 |
Why?
|
| Skin | 1 | 2004 | 4484 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1899 | 0.090 |
Why?
|
| Clinical Protocols | 2 | 2015 | 1440 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2004 | 15843 | 0.090 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 1972 | 0.090 |
Why?
|
| Precancerous Conditions | 4 | 2007 | 980 | 0.090 |
Why?
|
| Brachytherapy | 4 | 2007 | 1223 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 6935 | 0.090 |
Why?
|
| Cytogenetics | 1 | 2010 | 198 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2009 | 2358 | 0.090 |
Why?
|
| Relative Biological Effectiveness | 1 | 2011 | 312 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1994 | 1374 | 0.080 |
Why?
|
| Tongue Neoplasms | 3 | 1986 | 183 | 0.080 |
Why?
|
| Antibodies, Viral | 4 | 1986 | 3156 | 0.080 |
Why?
|
| Hematocrit | 1 | 2011 | 623 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2917 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 1995 | 735 | 0.080 |
Why?
|
| Focal Infection | 1 | 1989 | 9 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2011 | 416 | 0.080 |
Why?
|
| Length of Stay | 4 | 2022 | 6426 | 0.080 |
Why?
|
| Bilirubin | 1 | 2011 | 436 | 0.080 |
Why?
|
| Tuberous Sclerosis | 1 | 2017 | 1030 | 0.080 |
Why?
|
| SEER Program | 3 | 2011 | 1450 | 0.080 |
Why?
|
| Ice | 1 | 2009 | 102 | 0.080 |
Why?
|
| Empyema | 1 | 1988 | 41 | 0.080 |
Why?
|
| Survival Rate | 7 | 2020 | 12725 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 2 | 2012 | 876 | 0.080 |
Why?
|
| Platelet Count | 1 | 2011 | 781 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2011 | 603 | 0.080 |
Why?
|
| Tolonium Chloride | 1 | 2007 | 23 | 0.080 |
Why?
|
| Logistic Models | 6 | 2015 | 13255 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2014 | 5079 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 864 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5672 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3204 | 0.070 |
Why?
|
| Osteonecrosis | 2 | 2007 | 229 | 0.070 |
Why?
|
| Sutures | 1 | 2010 | 284 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2012 | 11076 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3466 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 108 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1008 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2015 | 4811 | 0.070 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 3416 | 0.070 |
Why?
|
| Patient Care Team | 1 | 1998 | 2521 | 0.070 |
Why?
|
| Thermoluminescent Dosimetry | 2 | 2004 | 27 | 0.070 |
Why?
|
| Hemostasis | 1 | 1990 | 467 | 0.070 |
Why?
|
| Jaw Diseases | 1 | 2007 | 92 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1596 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2012 | 4021 | 0.070 |
Why?
|
| Pancreatic Pseudocyst | 2 | 2004 | 110 | 0.070 |
Why?
|
| Hospitals, Teaching | 3 | 2005 | 1156 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1303 | 0.070 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2008 | 172 | 0.070 |
Why?
|
| Biomedical Research | 2 | 2020 | 3429 | 0.070 |
Why?
|
| Mouth Floor | 1 | 1986 | 38 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 4352 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 1378 | 0.070 |
Why?
|
| Escherichia coli Infections | 2 | 1995 | 518 | 0.070 |
Why?
|
| Stromal Cells | 2 | 2009 | 1330 | 0.070 |
Why?
|
| Musculoskeletal Diseases | 1 | 2012 | 598 | 0.060 |
Why?
|
| Water | 1 | 2012 | 1411 | 0.060 |
Why?
|
| Calibration | 2 | 2006 | 818 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2012 | 12341 | 0.060 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2005 | 21 | 0.060 |
Why?
|
| Creatinine | 1 | 2011 | 1899 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2010 | 909 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2007 | 562 | 0.060 |
Why?
|
| Lung | 3 | 2021 | 10002 | 0.060 |
Why?
|
| Urology | 2 | 2009 | 400 | 0.060 |
Why?
|
| Retroperitoneal Space | 2 | 1995 | 170 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 1116 | 0.060 |
Why?
|
| Anesthesiology | 1 | 2015 | 1120 | 0.060 |
Why?
|
| Piperazines | 2 | 2007 | 2523 | 0.060 |
Why?
|
| Trichosporon | 1 | 2004 | 9 | 0.060 |
Why?
|
| Costs and Cost Analysis | 3 | 2000 | 1668 | 0.060 |
Why?
|
| Communication | 1 | 2018 | 3873 | 0.060 |
Why?
|
| Young Adult | 8 | 2014 | 59255 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 496 | 0.060 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2004 | 52 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2510 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7391 | 0.060 |
Why?
|
| Ovarian Neoplasms | 4 | 2003 | 4878 | 0.060 |
Why?
|
| Robotics | 1 | 2010 | 819 | 0.060 |
Why?
|
| Gadolinium | 1 | 2009 | 960 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 280 | 0.060 |
Why?
|
| Patient Participation | 1 | 2013 | 1445 | 0.060 |
Why?
|
| Brachial Plexus | 1 | 2005 | 167 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 8656 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2373 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2007 | 459 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 6815 | 0.050 |
Why?
|
| Cautery | 1 | 2023 | 71 | 0.050 |
Why?
|
| Oxides | 2 | 1995 | 401 | 0.050 |
Why?
|
| Urinary Bladder Diseases | 1 | 2004 | 167 | 0.050 |
Why?
|
| Plants, Toxic | 1 | 1983 | 71 | 0.050 |
Why?
|
| Abdominal Pain | 2 | 2007 | 1071 | 0.050 |
Why?
|
| Reoperation | 1 | 2013 | 4303 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 1779 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2018 | 6567 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2007 | 3028 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2003 | 100 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2005 | 500 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2011 | 2927 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2007 | 635 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2010 | 1394 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 1463 | 0.050 |
Why?
|
| Splenectomy | 1 | 2004 | 391 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| Genomics | 1 | 2018 | 5821 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9420 | 0.050 |
Why?
|
| Specialties, Dental | 1 | 2001 | 35 | 0.050 |
Why?
|
| Benzydamine | 1 | 2001 | 3 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 3249 | 0.050 |
Why?
|
| Liposarcoma | 1 | 2004 | 289 | 0.050 |
Why?
|
| Oral Medicine | 1 | 2001 | 36 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2008 | 1242 | 0.050 |
Why?
|
| Prevalence | 2 | 2011 | 15732 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2014 | 2046 | 0.050 |
Why?
|
| Synovial Cyst | 1 | 2001 | 35 | 0.050 |
Why?
|
| Software Validation | 1 | 2001 | 59 | 0.050 |
Why?
|
| Stomatitis | 2 | 2001 | 271 | 0.050 |
Why?
|
| Embolization, Therapeutic | 2 | 2014 | 1418 | 0.050 |
Why?
|
| Posture | 1 | 2005 | 957 | 0.050 |
Why?
|
| Antifungal Agents | 2 | 2004 | 753 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 10766 | 0.050 |
Why?
|
| Abscess | 2 | 2004 | 606 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 1432 | 0.040 |
Why?
|
| Shoulder Pain | 1 | 2001 | 151 | 0.040 |
Why?
|
| Vasodilation | 1 | 2004 | 962 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 1984 | 988 | 0.040 |
Why?
|
| Hyperthermia, Induced | 4 | 2006 | 417 | 0.040 |
Why?
|
| Sex Ratio | 1 | 2000 | 108 | 0.040 |
Why?
|
| Nerve Compression Syndromes | 1 | 2001 | 160 | 0.040 |
Why?
|
| Esophagectomy | 1 | 2003 | 468 | 0.040 |
Why?
|
| Recurrence | 3 | 1999 | 8466 | 0.040 |
Why?
|
| Medical Records | 3 | 2006 | 1408 | 0.040 |
Why?
|
| Shoulder | 1 | 2001 | 300 | 0.040 |
Why?
|
| Neodymium | 1 | 1998 | 19 | 0.040 |
Why?
|
| Thorax | 2 | 2017 | 555 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2001 | 2827 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2000 | 325 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2001 | 165 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2004 | 1835 | 0.040 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2578 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1983 | 592 | 0.040 |
Why?
|
| Blood Donors | 1 | 2020 | 345 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 318 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 2005 | 1174 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2008 | 3551 | 0.040 |
Why?
|
| Pyrroles | 1 | 2004 | 1125 | 0.040 |
Why?
|
| Fluocinonide | 2 | 2001 | 9 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 15501 | 0.040 |
Why?
|
| Urogenital System | 1 | 1998 | 88 | 0.040 |
Why?
|
| Equipment Safety | 2 | 2001 | 249 | 0.040 |
Why?
|
| Urinary Tract | 2 | 1999 | 313 | 0.040 |
Why?
|
| Scattering, Radiation | 1 | 1999 | 490 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 1998 | 510 | 0.040 |
Why?
|
| Career Choice | 1 | 2024 | 756 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1085 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2002 | 553 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2017 | 364 | 0.040 |
Why?
|
| Carbon Dioxide | 3 | 1998 | 1147 | 0.040 |
Why?
|
| Education | 1 | 2020 | 537 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 1651 | 0.040 |
Why?
|
| Ureteral Diseases | 1 | 1997 | 63 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1999 | 426 | 0.030 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1997 | 42 | 0.030 |
Why?
|
| Hospital Departments | 1 | 1997 | 134 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2007 | 727 | 0.030 |
Why?
|
| Demography | 1 | 2001 | 1648 | 0.030 |
Why?
|
| Rectum | 2 | 2003 | 892 | 0.030 |
Why?
|
| Iron | 2 | 1995 | 1793 | 0.030 |
Why?
|
| Indoles | 1 | 2004 | 1833 | 0.030 |
Why?
|
| Radio Waves | 1 | 2017 | 251 | 0.030 |
Why?
|
| Azathioprine | 2 | 2001 | 354 | 0.030 |
Why?
|
| Educational Status | 1 | 2023 | 2522 | 0.030 |
Why?
|
| Smoking | 8 | 1997 | 9053 | 0.030 |
Why?
|
| Immunoglobulin M | 3 | 1986 | 1526 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 695 | 0.030 |
Why?
|
| Physicians | 2 | 2015 | 4591 | 0.030 |
Why?
|
| Burnout, Professional | 1 | 2024 | 704 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22176 | 0.030 |
Why?
|
| Muscles | 1 | 2020 | 1576 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 12463 | 0.030 |
Why?
|
| Diatrizoate | 1 | 1994 | 81 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 1489 | 0.030 |
Why?
|
| Secretory Rate | 1 | 1994 | 81 | 0.030 |
Why?
|
| Bethanechol | 1 | 1994 | 12 | 0.030 |
Why?
|
| Leadership | 1 | 2024 | 1385 | 0.030 |
Why?
|
| Age Distribution | 1 | 2000 | 2880 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1994 | 306 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 2047 | 0.030 |
Why?
|
| Collateral Circulation | 1 | 1995 | 294 | 0.030 |
Why?
|
| Infarction | 1 | 1995 | 248 | 0.030 |
Why?
|
| Iliac Artery | 1 | 1995 | 343 | 0.030 |
Why?
|
| Renal Artery | 1 | 1995 | 351 | 0.030 |
Why?
|
| Receptors, Muscarinic | 1 | 1994 | 157 | 0.030 |
Why?
|
| Comorbidity | 1 | 2008 | 10508 | 0.030 |
Why?
|
| Universal Precautions | 1 | 1993 | 34 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2007 | 13642 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 1654 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 2425 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 787 | 0.030 |
Why?
|
| Treatment Failure | 1 | 1999 | 2644 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 8552 | 0.030 |
Why?
|
| Sex Factors | 3 | 2001 | 10553 | 0.030 |
Why?
|
| Suspensions | 1 | 2012 | 66 | 0.030 |
Why?
|
| Prednisone | 2 | 2001 | 1563 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1995 | 625 | 0.030 |
Why?
|
| Age Factors | 3 | 2014 | 18398 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 962 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 5305 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 1998 | 990 | 0.030 |
Why?
|
| Journal Impact Factor | 1 | 2013 | 153 | 0.030 |
Why?
|
| Ischemia | 1 | 2001 | 1883 | 0.020 |
Why?
|
| Decision Trees | 1 | 2014 | 504 | 0.020 |
Why?
|
| Bleeding Time | 1 | 1991 | 83 | 0.020 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 1991 | 38 | 0.020 |
Why?
|
| Hernia, Ventral | 1 | 1995 | 218 | 0.020 |
Why?
|
| Punctures | 1 | 1993 | 366 | 0.020 |
Why?
|
| Hospital Costs | 1 | 1998 | 947 | 0.020 |
Why?
|
| Ovary | 3 | 2001 | 959 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4111 | 0.020 |
Why?
|
| Carotenoids | 1 | 1994 | 621 | 0.020 |
Why?
|
| Health Promotion | 1 | 2023 | 2214 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 655 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1486 | 0.020 |
Why?
|
| Capsule Endoscopy | 1 | 2012 | 100 | 0.020 |
Why?
|
| Colectomy | 1 | 1996 | 688 | 0.020 |
Why?
|
| Penile Diseases | 1 | 1991 | 45 | 0.020 |
Why?
|
| Endoscopy | 2 | 1998 | 1851 | 0.020 |
Why?
|
| Stomach | 2 | 2012 | 696 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 30054 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2004 | 3963 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 2020 | 0.020 |
Why?
|
| Vitamin E | 1 | 1994 | 872 | 0.020 |
Why?
|
| Immunoglobulin A | 2 | 1984 | 978 | 0.020 |
Why?
|
| Angiography | 1 | 1995 | 1595 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1858 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2000 | 1813 | 0.020 |
Why?
|
| Saliva | 1 | 1994 | 828 | 0.020 |
Why?
|
| California | 2 | 1991 | 1430 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1745 | 0.020 |
Why?
|
| Benzamides | 2 | 2007 | 1370 | 0.020 |
Why?
|
| Accident Prevention | 1 | 1989 | 76 | 0.020 |
Why?
|
| Research Design | 1 | 2005 | 6180 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3882 | 0.020 |
Why?
|
| Hepatic Duct, Common | 1 | 1989 | 48 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2046 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1986 | 4544 | 0.020 |
Why?
|
| Adenoma | 1 | 1999 | 2160 | 0.020 |
Why?
|
| Candida albicans | 2 | 1997 | 372 | 0.020 |
Why?
|
| Cholecystitis | 1 | 1989 | 180 | 0.020 |
Why?
|
| Prostate | 1 | 1996 | 1773 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2023 | 4812 | 0.020 |
Why?
|
| Americas | 1 | 2007 | 111 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 447 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 2 | 2000 | 462 | 0.020 |
Why?
|
| Gastrostomy | 1 | 1990 | 323 | 0.020 |
Why?
|
| Colon | 1 | 1995 | 1792 | 0.020 |
Why?
|
| Pleura | 1 | 1988 | 245 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2015 | 9646 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 1997 | 491 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7827 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1994 | 1265 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 702 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4124 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 350 | 0.020 |
Why?
|
| Antioxidants | 1 | 1994 | 1668 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Minerals | 1 | 2007 | 283 | 0.020 |
Why?
|
| Mouth | 1 | 1988 | 381 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 2218 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 3826 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 5492 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2011 | 7967 | 0.020 |
Why?
|
| Cholestasis | 1 | 1989 | 378 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2007 | 368 | 0.020 |
Why?
|
| Uncertainty | 1 | 2010 | 754 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 1988 | 341 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 1984 | 88 | 0.010 |
Why?
|
| Chromans | 1 | 2004 | 117 | 0.010 |
Why?
|
| Radiotherapy | 2 | 2001 | 1499 | 0.010 |
Why?
|
| History, 18th Century | 1 | 2004 | 207 | 0.010 |
Why?
|
| Palatal Neoplasms | 1 | 1984 | 37 | 0.010 |
Why?
|
| Neural Conduction | 1 | 2005 | 441 | 0.010 |
Why?
|
| Paralysis | 1 | 2005 | 250 | 0.010 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2004 | 49 | 0.010 |
Why?
|
| Clone Cells | 1 | 2007 | 1659 | 0.010 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 132 | 0.010 |
Why?
|
| Rheumatoid Factor | 1 | 1984 | 185 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1768 | 0.010 |
Why?
|
| Ferrosoferric Oxide | 2 | 1995 | 348 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1989 | 718 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2003 | 1394 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2007 | 1494 | 0.010 |
Why?
|
| Proctoscopy | 1 | 2003 | 40 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 5440 | 0.010 |
Why?
|
| Biliary Tract Diseases | 1 | 2004 | 159 | 0.010 |
Why?
|
| Magnetite Nanoparticles | 2 | 1995 | 318 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1994 | 2036 | 0.010 |
Why?
|
| Child | 2 | 2003 | 80156 | 0.010 |
Why?
|
| Dextrans | 2 | 1995 | 574 | 0.010 |
Why?
|
| Tobacco, Smokeless | 1 | 1984 | 133 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2004 | 393 | 0.010 |
Why?
|
| Brachial Artery | 1 | 2004 | 366 | 0.010 |
Why?
|
| Prednisolone | 1 | 2003 | 326 | 0.010 |
Why?
|
| Leukoplakia | 1 | 1982 | 18 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 997 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 3461 | 0.010 |
Why?
|
| Measles virus | 1 | 1982 | 67 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12059 | 0.010 |
Why?
|
| Habits | 1 | 1983 | 147 | 0.010 |
Why?
|
| Oropharynx | 1 | 1983 | 138 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 883 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 629 | 0.010 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2004 | 185 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2004 | 506 | 0.010 |
Why?
|
| Clobetasol | 1 | 2001 | 33 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 461 | 0.010 |
Why?
|
| Mouthwashes | 1 | 2001 | 57 | 0.010 |
Why?
|
| Swine | 2 | 2005 | 5915 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1994 | 3600 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1989 | 1490 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 778 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 664 | 0.010 |
Why?
|
| Lasers | 1 | 2005 | 952 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1983 | 728 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1983 | 1060 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 26127 | 0.010 |
Why?
|
| Electric Impedance | 1 | 2005 | 757 | 0.010 |
Why?
|
| Digestive System | 1 | 2001 | 244 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 1611 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 9177 | 0.010 |
Why?
|
| Aspirin | 1 | 1991 | 3133 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 1150 | 0.010 |
Why?
|
| Mammography | 1 | 2010 | 2430 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1983 | 478 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2001 | 704 | 0.010 |
Why?
|
| Case Management | 1 | 2001 | 272 | 0.010 |
Why?
|
| Methods | 2 | 1990 | 1067 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 2000 | 292 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 1886 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 1999 | 90 | 0.010 |
Why?
|
| Epithelium | 2 | 1997 | 1603 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2005 | 1440 | 0.010 |
Why?
|
| Adiponectin | 1 | 2004 | 1113 | 0.010 |
Why?
|
| Biomedical Engineering | 1 | 2000 | 288 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2001 | 9319 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 2112 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1983 | 756 | 0.010 |
Why?
|
| Cysts | 1 | 2003 | 681 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1993 | 4793 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 2001 | 2898 | 0.010 |
Why?
|
| Erythroplasia | 1 | 1997 | 1 | 0.010 |
Why?
|
| India | 1 | 2004 | 2348 | 0.010 |
Why?
|
| Ketoconazole | 1 | 1997 | 97 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 14607 | 0.010 |
Why?
|
| Technology, Radiologic | 1 | 1997 | 160 | 0.010 |
Why?
|
| Data Display | 1 | 1997 | 175 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1997 | 330 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1998 | 9031 | 0.010 |
Why?
|
| Fluconazole | 1 | 1997 | 157 | 0.010 |
Why?
|
| Chymotrypsinogen | 1 | 1976 | 5 | 0.010 |
Why?
|
| Endoscopes | 1 | 1997 | 168 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2397 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 2461 | 0.010 |
Why?
|
| Trypsinogen | 1 | 1976 | 84 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 8002 | 0.010 |
Why?
|
| Amylases | 1 | 1976 | 171 | 0.010 |
Why?
|
| Calcinosis | 1 | 2005 | 1469 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 1318 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1998 | 42230 | 0.010 |
Why?
|
| Torsion Abnormality | 1 | 1996 | 91 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1983 | 3810 | 0.010 |
Why?
|
| Reference Values | 1 | 1982 | 4920 | 0.010 |
Why?
|
| Empyema, Pleural | 1 | 1995 | 61 | 0.010 |
Why?
|
| DNA | 1 | 1988 | 7213 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1994 | 114 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 457 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1998 | 767 | 0.010 |
Why?
|
| Klebsiella Infections | 1 | 1995 | 146 | 0.010 |
Why?
|
| Enterococcus faecalis | 1 | 1995 | 245 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 1705 | 0.010 |
Why?
|
| Injections | 1 | 1997 | 831 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1993 | 169 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 6312 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1994 | 158 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 3492 | 0.010 |
Why?
|
| beta Carotene | 1 | 1994 | 523 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 1459 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 3839 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1995 | 343 | 0.010 |
Why?
|
| Abdominal Muscles | 1 | 1993 | 169 | 0.010 |
Why?
|
| Color | 1 | 1994 | 299 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2001 | 2161 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 1995 | 432 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 1809 | 0.010 |
Why?
|
| Animals | 5 | 2007 | 168467 | 0.010 |
Why?
|
| Penis | 1 | 1991 | 212 | 0.010 |
Why?
|
| Insulin | 1 | 2004 | 6597 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 6032 | 0.010 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1990 | 166 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1994 | 1814 | 0.000 |
Why?
|
| Neurilemmoma | 1 | 1994 | 526 | 0.000 |
Why?
|
| Gangrene | 1 | 1989 | 91 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 4176 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1998 | 3769 | 0.000 |
Why?
|
| Internal Medicine | 1 | 1994 | 1051 | 0.000 |
Why?
|
| Equipment and Supplies | 1 | 1989 | 273 | 0.000 |
Why?
|
| Risk | 2 | 1994 | 9610 | 0.000 |
Why?
|
| Pressure | 1 | 1989 | 1154 | 0.000 |
Why?
|
| Alcoholism | 1 | 1995 | 1973 | 0.000 |
Why?
|
| Computer Simulation | 1 | 1997 | 6241 | 0.000 |
Why?
|
| Bile Duct Neoplasms | 1 | 1989 | 605 | 0.000 |
Why?
|
| Alcohol Drinking | 1 | 1994 | 4028 | 0.000 |
Why?
|
| Jaw | 1 | 1981 | 93 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2002 | 23447 | 0.000 |
Why?
|
| Mandible | 1 | 1981 | 753 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1981 | 1189 | 0.000 |
Why?
|
| Rabbits | 1 | 1976 | 4772 | 0.000 |
Why?
|